Tonix Pharmaceuticals stock halted ahead of FDA approval news
Nasus Pharma Ltd. (NYSE American: NSRX) priced its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before deducting underwriting fees and expenses, according to a company statement.
The Tel Aviv-based clinical-stage pharmaceutical company granted underwriters a 45-day option to purchase up to an additional 187,500 shares at the offering price to cover over-allotments. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC served as joint bookrunners for the offering.
The company’s shares received approval for listing on the NYSE American and began trading on August 13, 2025, under the ticker symbol "NSRX." The offering closed on August 14, 2025.
Nasus Pharma stated it plans to use net proceeds to advance development of its intranasal epinephrine program, including manufacturing scale-up and additional Phase 2 studies. Remaining funds will support general administrative purposes, working capital, and capital expenditures.
The Securities and Exchange Commission declared the company’s registration statement on Form F-1 (File No. 333-288582) effective on August 12, 2025.
Nasus Pharma develops intranasal powder products for acute medical conditions. Its lead product candidate, NS002, is an intranasal powder epinephrine treatment designed as an alternative to epinephrine autoinjectors for patients with anaphylaxis. The company’s proprietary powder-based intranasal technology uses the nasal cavity’s vascular network for drug absorption.